Cargando…

Heparin – Messias or Verschlimmbesserung?

A heightened risk of thrombosis noted early on with the severe acute respiratory syndrome coronavirus 2 infection led to the widespread use of heparin anticoagulation in the coronavirus disease 2019 (COVID‐19) pandemic. However, reports soon started appearing in the literature where an apparent fail...

Descripción completa

Detalles Bibliográficos
Autores principales:	Swan, Dawn, Carrier, Marc, Lisman, Ton, Thachil, Jecko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906358/ https://www.ncbi.nlm.nih.gov/pubmed/34272818 http://dx.doi.org/10.1111/jth.15464

Ejemplares similares

Differentiating biochemical from clinical heparin resistance in COVID-19
por: Lisman, Ton, et al.
Publicado: (2020)

The versatile heparin in COVID‐19
por: Thachil, Jecko
Publicado: (2020)

Non‐factor therapies for bleeding disorders: A primer for the general haematologist
por: Swan, Dawn, et al.
Publicado: (2022)

Practical management of the haemorrhagic complications of myeloproliferative neoplasms
por: Jones, Edward, et al.
Publicado: (2022)

Thromboprophylaxis in COVID-19 – Rationale and considerations
por: Bristogiannis, Sotirios, et al.
Publicado: (2021)

The concept of rebalanced hemostasis in patients with liver disease: Communication from the ISTH SSC working group on hemostatic management of patients with liver disease
por: Lisman, Ton, et al.
Publicado: (2021)

Type and dose of heparin in Covid‐19: Reply
por: Thachil, Jecko, et al.
Publicado: (2020)

Lessons learnt from COVID‐19 coagulopathy
por: Thachil, Jecko
Publicado: (2021)

The implications of aspirin resistance in renal failure
por: Thachil, Jecko
Publicado: (2008)

Abnormal coagulation tests before kidney biopsies—what next?
por: Thachil, Jecko
Publicado: (2013)

The difficult distinction between haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura
por: Thachil, Jecko
Publicado: (2008)

Usefulness of Combining D-Dimers with Thromboelastography
por: Thachil, Jecko
Publicado: (2020)

Hypoxia—An overlooked trigger for thrombosis in COVID‐19 and other critically ill patients
por: Thachil, Jecko
Publicado: (2020)

Approach to the Diagnosis and Classification of Blood Cell Disorders
por: Thachil, Jecko, et al.
Publicado: (2017)

The application of anticoagulant therapy to sepsis
por: Thachil, Jecko, et al.
Publicado: (2017)

Clinical significance of measuring plasminogen activator inhibitor-1 in sepsis
por: Iba, Toshiaki, et al.
Publicado: (2017)

Asymptomatic Joint Bleeding and Joint Health in Hemophilia: A Review of Variables, Methods, and Biomarkers
por: Gooding, Richard, et al.
Publicado: (2021)

Thromboembolism in nephrotic syndrome: controversies and uncertainties
por: Parker, Kathrine, et al.
Publicado: (2023)

A proposal for staging COVID‐19 coagulopathy
por: Thachil, Jecko, et al.
Publicado: (2020)

Heparins have adequate ex vivo anticoagulant effects in hospitalized patients with cirrhosis
por: van den Boom, Bente P., et al.
Publicado: (2021)

Thrombomodulin in disseminated intravascular coagulation and other critical conditions—a multi-faceted anticoagulant protein with therapeutic potential
por: Ito, Takashi, et al.
Publicado: (2019)

Platelet–neutrophil interactions as drivers of inflammatory and thrombotic disease
por: Lisman, Ton
Publicado: (2017)

Haematological Diseases in the Tropics
por: Thachil, Jecko, et al.
Publicado: (2014)

Proposal of the Definition for COVID-19-Associated Coagulopathy
por: Iba, Toshiaki, et al.
Publicado: (2021)

DIC in Pregnancy – Pathophysiology, Clinical Characteristics, Diagnostic Scores, and Treatments
por: Erez, Offer, et al.
Publicado: (2022)

Anticoagulation in chronic kidney disease patients—the practical aspects
por: Hughes, Stephen, et al.
Publicado: (2014)

Coagulation abnormalities and thrombosis in patients with COVID-19
por: Levi, Marcel, et al.
Publicado: (2020)

The unique characteristics of COVID-19 coagulopathy
por: Iba, Toshiaki, et al.
Publicado: (2020)

Pathogenesis, prevention, and management of bleeding and thrombosis in patients with liver diseases
por: Lisman, Ton, et al.
Publicado: (2017)

UK prescribing practice of anticoagulants in patients with chronic kidney disease: a nephrology and haematology-based survey
por: Parker, Kathrine, et al.
Publicado: (2023)

Early Host Interactions That Drive the Dysregulated Response in Sepsis
por: Kerrigan, Steven W., et al.
Publicado: (2019)

Is it hyperfibrinolysis or fibrinolytic shutdown in severe COVID-19?
por: Nielsen, Nathan D., et al.
Publicado: (2022)

Bleeding and Thrombosis in Patients With Cirrhosis: What’s New?
por: Lisman, Ton
Publicado: (2023)

A systematic review of the efficacy and safety of anticoagulants in advanced chronic kidney disease
por: Parker, Kathrine, et al.
Publicado: (2022)

New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey
por: Iba, Toshiaki, et al.
Publicado: (2017)

The Comparison of the Protective Effects of α- and β-Antithrombin against Vascular Endothelial Cell Damage Induced by Histone in Vitro
por: Iba, Toshiaki, et al.
Publicado: (2017)

POINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? Yes
por: Tritschler, Tobias, et al.
Publicado: (2022)

Longitudinal Analysis of Prophylactic Anticoagulation in Primary Nephrotic Syndrome: Low Incidence of Thromboembolic Complications
por: McDonnell, Thomas, et al.
Publicado: (2023)

Heparin and Heparin-Derivatives in Post-Subarachnoid Hemorrhage Brain Injury: A Multimodal Therapy for a Multimodal Disease
por: Hayman, Erik G., et al.
Publicado: (2017)

Fibrin clot properties and thrombus composition in cirrhosis
por: Driever, Ellen G., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_oh03ombimkn9jcoeamvdddf0ur